Abstract
Background Surgical intervention in the setting of cardiogenic shock (CS) is burdened with high mortality. Due to acute condition, detailed diagnoses and risk assessment is often precluded. Atrial fibrillation (AF) is a risk factor for perioperative complications and worse survival but little is known about AF patients operated in CS. Current analysis aimed to determine prognostic impact of preoperative AF in patients undergoing heart surgery in CS.
Methods We analyzed data from the Polish National Registry of Cardiac Surgery (KROK) Procedures. Between 2012 and 2021, 4,852 patients presented with CS and were referred for cardiac surgery in 37 centers. Total of 624 (13%) patients had AF history. Cox proportional hazards models were used for computations. Propensity score (nearest neighbor) matching for the comparison of patients with and without AF was performed.
Results Median follow-up was 4.6 years (max.10.0), mean age was 62 (±15) years and 68% patients were men. Thirty-day mortality was 36%. The origin of CS included acute myocardial infarction (36%), acute aortic dissection (22%) and valvular dysfunction (13%). In an unadjusted analysis, patients with underlying AF had almost 20% higher mortality risk (HR 1.19, 95% CIs 1.06-1.34; P=0.004). Propensity score matching returned 597 pairs with similar baseline characteristics; AF remained a significant prognostic factor for worse survival (HR 1.19, 95% CI 1.00-1.40; P=0.045).
Conclusions Among patients with CS referred for cardiac surgery, history of AF was a significant risk factor for mortality. Role of concomitant AF ablation and/or left atrial appendage occlusion should be addressed in the future.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
none
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Study was approved by Institutional Board of CSK MSWiA
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
KROK Investigators: Lech Anisimowicz MD, PhD (Bydgoszcz); Krzysztof Bartuś MD, PhD (Kraków); Andrzej Biederman MD, PhD (Warszawa); Dariusz Borkowski MD (Radom); Mirosław Brykczyński MD, PhD (Szczecin); Paweł Bugajski MD, PhD (Poznań); Marian Burysz (Grudziądz) Paweł Cholewiński (Radom); Romuald Cichoń MD, PhD (Warszawa); Marek Cisowski MD, PhD (Bielsko-Biała); Marek Deja MD, PhD (Katowice); Antoni Dziatkowiak MD, PhD (Kraków); Tadeusz Gburek MD (Zamość); Witold Gerber MD (Bielsko-Biała); Leszek Gryczko MD (Warszawa); Ireneusz Haponiuk MD (Gdańsk); Piotr Hendzel MD, PhD (Warszawa); Tomasz Hirnle MD, PhD (Białystok); Stanisław Jabłonka MD, PhD (Lublin); Krzysztof Jarmoszewicz MD (Wejherowo); Jarosław Jasiński MD (Zielona Góra); Marek Jasiński MD, PhD (Wrocław); Ryszard Jaszewski MD, PhD (Łódź); Marek Jemielity MD, PhD (Poznań); Ryszard Kalawski MD, PhD (Poznań); Bogusław Kapelak MD, PhD (Kraków); Maciej A. Karolczak MD, PhD (Warszawa); Jacek Kaperczak MD (Opole); Piotr Knapik MD, PhD (Zabrze); Michał Krejca MD, PhD (Łódź); Wojciech Kustrzycki MD, PhD (Wrocław); Mariusz Kuśmierczyk MD, PhD (Warszawa); Paweł Kwinecki MD (Wrocław); Leszek Markuszewski MD, PhD (Łódź); Bohdan Maruszewski (Warszawa); Maurycy Missima MD (Bydgoszcz); Jacek J Moll MD, PhD (Łódź); Wojciech Ogorzeja MD (Grudziądz); Jacek Pająk MD (Katowice); Michał Pasierski (Warszawa); Wojciech Pawliszak MD (Bydgoszcz); Edward Pietrzyk MD (Kielce); Grzegorz Religa MD (Łódź); Jan Rogowski MD, PhD (Gdańsk); Jacek Różański MD, PhD (Warszawa); Jerzy Sadowski MD, PhD (Kraków); Girish Sharma MD (Wrocław); Janusz Skalski MD, PhD (Kraków); Jacek Skiba MD (Wrocław); Ryszard Stanisławski MD (Nowa Sól); Janusz Stążka MD, PhD (Lublin); Sebastian Stec MD, PhD (Warsaw); Piotr Stępiński MD (Nowa Sól); Grzegorz Suwalski MD (Warszawa); Kazimierz Suwalski MD, PhD (Warszawa); Piotr Suwalski MD, PhD (Warszawa); Łukasz Tułecki MD (Zamość); Kazimierz Widenka MD, PhD (Rzeszów); Waldemar Wierzba MD (Warszawa); Michał Wojtalik MD, PhD (Poznań); Stanisław Woś MD, PhD (Katowice); Michał Oskar Zembala MD, PhD (Zabrze) and Piotr Żelazny MD (Olsztyn).
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
